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Overnutrition and modern diets containing high proportions of saturated fat are among
the major factors contributing to a low-grade state of inflammation, hyperglycemia
and dyslipidemia. In the last decades, the global rise of type 2 diabetes and obesity
prevalence has elicited a great interest in understanding how changes in metabolic
function lead to an increased risk for premature brain aging and the development of
neurodegenerative disorders such as Alzheimer’s disease (AD). Cognitive impairment
and decreased neurogenic capacity could be a consequence of metabolic disturbances.
In these scenarios, the interplay between inflammation and insulin resistance could
represent a potential therapeutic target to prevent or ameliorate neurodegeneration and
cognitive impairment. The present review aims to provide an update on the impact of
metabolic stress pathways on AD with a focus on inflammation and insulin resistance
as risk factors and therapeutic targets.
Keywords: Alzheimer’s disease, metabolic disorders, cognitive impairment, insulin resistance, inflammation,
therapies
INTRODUCTION
Modern lifestyle is associated with detrimental behavioral and dietary habits such as sedentarism
and high dietary intake of saturated fats and refined sugars. These, among other habits, are
determinants for the development of obesity, type 2 diabetes (T2D) and associated conditions
that have a straightforward impact on several systems including the central nervous system (CNS),
thereby heightening the risk for cognitive impairment and neuropsychiatric diseases.
Obesity is a multifactorial disease mainly defined as an excessive accumulation and abnormal
distribution of adipose tissue in the body. In terms of prevalence, overweight and obesity rates
have increased alarmingly in the last decades currently reaching global epidemic levels (Who,
2018). Almost 40% of the world’s adult population was overweight in 2016 and 13% was obese,
with the aggravating fact of this trend being featured also at juvenile stages. Moreover, overweight
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and obesity constitute the major risk factors for the development
of T2D and metabolic syndrome (MetS). As for diabetes, the
main hallmark is the presence of increased blood glucose
levels and its prevalence was estimated to be close to 9%
of the world’s population (Idf, 2017). The most common
form is the T2D, representing 85–95% of the cases, closely
associated with metabolic factors such as obesity. Metabolic
syndrome encompasses a variety of conditions associated with
cardiometabolic risk, a cluster of alterations including high blood
pressure, hyperglycemia, hyperinsulinemia, dyslipidemia and
increased abdominal fat or obesity. However, these conditions
may not manifest in the same way in all patients. Its prevalence
has dramatically increased in a similar fashion as obesity in
all age groups (Bussler et al., 2017). Although each of the
pathologies stated above has its own features, they are intimately
related, sharing components, common risk factors and also
being part of the etiology of one another. Therefore, one
could attempt to focus on their shared pathways in order to
discuss potential mechanisms involved in the development of
associated pathologies.
Inflammation and insulin resistance are among the most
common phenomena underlying the pathophysiology of obesity-
and T2D- related diseases and, interestingly, also consistently
found in several neuropsychiatric conditions (Parimisetty et al.,
2016; O’Brien et al., 2017; Ying et al., 2020). As it will be further
discussed ahead, in neurodegenerative conditions associated with
brain aging, the hippocampus is one of the most vulnerable and
primarily affected structures, showing atrophy and alterations
in neuroplasticity mechanisms related to synaptic connectivity
and adult neurogenesis leading to cognitive dysfunction (Mu
and Gage, 2011). The fact that chronic metabolic disturbances
can also negatively affect such plasticity mechanisms in addition
to their association with cognitive deficits and mood alterations
(Biro and Wien, 2010; Puder and Munsch, 2010), suggests there
are converging pathways of metabolic stress and aging.
In the last decades, it has been reported that T2D, obesity,
hypertension and sedentarism are among the main modifiable
risk factors for neurodegenerative diseases (Bruce-Keller et al.,
2009). In particular, in this review we will focus on Alzheimer’s
disease (AD) as it is the most prevalent neurodegenerative
disease, the major cause of dementia and has a strong association
with metabolic disorders and related cardiovascular risk factors.
From several points of view, AD and obesity constitute very
relevant public health concerns due to the economic and social
burden of the diseases. The economic burden of AD, that was
estimated to be more than $300 billion in 2020 only in the
United States, is not only related to direct costs such as diagnosis,
drug therapy, hospitalization and specialized nursing or home
care but also with the quality of life of both patients and caregivers
in such a progressive and long- term disease (Alzheimer’s-
Association., 2020). Global obesity economic burden has been
estimated to be two trillion USD in 2014, accounting for a
20% of the total health care and is also related to decreased
productivity due to associated disease disability and promotion
of premature aging (Tremmel et al., 2017). These diseases’
impact over public health could be even much greater if we
considered at least four important factors: increasing obesity
rates in younger generations, diagnosis underestimation, obesity
comorbidities and the lack of effective therapies to mitigate
AD-like neurodegeneration.
Taking the above into account, the relevance and interrelation
of both metabolic and neurodegenerative health domains
leads to the development of a research field devoted to the
study of shared pathways in order to better comprehend their
dynamics and identify potential solutions (Figure 1). Obesity-
induced brain inflammation, as a common phenomenon
involved in the increased risk for brain dysfunction, could
act as a trigger and also as an exacerbating factor in the
development of neurodegenerative disorders. Therefore,
in this review we will discuss the particular effect of the
mentioned metabolic disorders on brain plasticity and
the potentiality for inflammatory and associated insulin-
resistance mediators as therapeutic targets in AD. Analyzing
existing interventions that address either insulin signaling or
inflammation might contribute to the understanding of brain
FIGURE 1 | Shared pathophysiological pathways and synergic burden of
obesity-related disorders and Alzheimer’s disease.
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METABOLIC RISK FACTORS FOR
ALZHEIMER’S DISEASE
Together with obesity, both mood and neurocognitive disorders
are highly prevalent public health concerns and a bidirectional
relationship among them has been suggested. Several studies
have recently shown a strong association between metabolic
disturbances and the development of anxiety-related disorders
and poor cognitive outcomes (Avinun and Hariri, 2019; Ronan
et al., 2019; van Duinkerken and Ryan, 2019), with higher rates
of anxiety and depression found in overweight and obese people
(Luppino et al., 2010; Gomes et al., 2019; James et al., 2020).
Interestingly, both anxiety and depression are associated with
an increased likelihood of developing AD (Becker et al., 2018;
Canton-Habas et al., 2020).
As life expectancy has constantly grown, brain aging-
related diseases have increased in a similar fashion. Among
neurodegenerative disorders, AD is the most common form
of age-related dementia. There are approximately 50 million
people worldwide suffering from dementia and 60–70% of
the cases may be attributed to AD, according to the World
Health Organization (Who, 2020). While age is the main
risk factor associated to the development of sporadic AD,
increasing the chances by 50% every 5 years after 65 years
old and reaching a 30–50% prevalence after 85 years of age
(Alzheimer’s-Association., 2020), it has been reported that T2D
and obesity, independently, are associated with an approximate
two-to-threefold increased chance of developing AD (Bruce-
Keller et al., 2009). Other risk factors for sporadic AD, which
constitute more than 95% of AD cases, are the presence of
the ε4 allele for apolipoprotein E (APOE) (Morris et al., 2017),
hypertension, atherosclerosis, hypercholesterolemia, traumatic
brain injury, among others (Edwards et al., 2019). Familial AD,
which accounts for 5% of total AD cases, is associated with
inherited mutations in the amyloid precursor protein (APP)
gene or in the genes for the enzymes that process APP to
produce amyloid β (Aβ). Clinically, AD is characterized by
the progressive loss of memory and cognitive abilities that
ultimately lead to severe impairments in daily life activities.
Cerebral extracellular accumulation of Aβ peptide plaques and
intraneuronal neurofibrillary tangles of hyperphosphorylated
Tau are the main histopathological hallmarks. Among the
shared brain alterations between metabolic pathologies and
neurodegeneration, insulin resistance constitutes one of the
main factors. A considerable body of evidence suggests a
relevant overlap across T2D and AD including risk, comorbidity
and pathophysiological pathways. As a matter of fact, though
controversial, some authors propose that AD might represent
the so-called “Type 3 diabetes,” given that initial stages of the
disease related to cognitive dysfunction go along with multiple
alterations of the insulin pathway in the hippocampus (de la
Monte and Tong, 2014; Arnold et al., 2018).
The impact of midlife obesity in cognitive decline has been
extensively studied and even considered to be an early predictor
of AD (Dahl et al., 2010; Chuang et al., 2016; Gottesman et al.,
2017). High levels of saturated fatty acid in the cerebrospinal
fluid (CSF) of overweight patients with related metabolic
comorbidities correlate with amnestic mild cognitive impairment
(MCI) (Melo et al., 2020). However, the relevance of obesity
may be somewhat controversial across different age groups,
particularly depending on the phenotypic parameter assessed.
For instance, while a high body mass index (BMI > 25 kg/m2)
in early and midlife obese patients has been associated with the
development of cognitive impairment, it is more controversial
in the elderly since some reports support the same relationship
between both phenomena (Biro and Wien, 2010; Benito-Leon
et al., 2013; Melo et al., 2020) while others have not found a
significant association (Dahl and Hassing, 2013; Wang et al.,
2016; Deckers et al., 2017). In that sense, some studies claim
that indirect parameters associated with obesity, such as body fat
distribution, hyperglycemia or high-fat diet (HFD) consumption,
exhibit higher correlation with cognitive dysfunction in aged
cohorts (Assuncao et al., 2018). A large longitudinal analysis
by Mac Giollabhui et al. (2020) has shown that higher BMI
in a cohort of adolescents predicts a worse performance of
executive function and greater depression risk, in a context of
peripheral inflammation.
Another obesity-related factor that has been associated with
an increased risk of AD is dyslipidemia. Studies in animal
models have shown that high consumption of cholesterol
and hypercholesterolemia are associated with increased Aβ
aggregation and neuroinflammation (Sparks et al., 1994;
Zatta et al., 2002; Xue et al., 2007). Correspondingly, high
cholesterolemia in middle-aged humans is linked with an
increased risk for AD in later life compared with a control
population (Solomon et al., 2009) and a lipid profile showing high
levels of low-density lipoprotein (LDL) cholesterol and low levels
of high-density lipoprotein (HDL) cholesterol is associated with
increased Aβ levels in the brain (Reed et al., 2014). However,
a recent meta-analysis has found that AD risk is increased in
individuals with high LDL cholesterol blood levels but not in
those with high levels of HDL cholesterol, total cholesterol or
triglycerides (Saiz-Vazquez et al., 2020). Even though cholesterol
does not cross the blood–brain barrier (BBB) in physiological
conditions, cholesterol oxidized products like oxysterols can
cross it and may play a role in memory consolidation and AD
pathophysiology (Lutjohann et al., 1996; Kotti et al., 2006).
Regarding experimental data, our group and others have
shown neurological consequences associated with cognitive
dysfunction and emotional processing alterations in obesogenic
contexts. Exposure to a HFD promotes an altered behavioral
profile with diminished spatial memory, impaired daily life
activities, as well as anxiety and depressive-like behaviors in
young adult mice (Vinuesa et al., 2016) and cognitive decline
in aged mice (Wei et al., 2018). Likewise, HFD has shown to
exacerbate brain pathology and related behavioral impairment
in APP/PS1 and 3xTg-AD mouse models of AD (Theriault
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et al., 2016; Sah et al., 2017; Bracko et al., 2020), reinforcing
the relevant crosstalk between metabolic and age-associated
brain dysfunction.
In the following sections of this review, we will provide
an overview of the phenomena in common between the
aforementioned metabolic and neurodegenerative domains and
associated therapeutic approaches, in order to ascertain the




INSULIN RESISTANCE IN THE
INTERFACE BETWEEN METABOLIC AND
NEURODEGENERATIVE CONDITIONS
Systemic Inflammation
Although many cellular and molecular pathways are affected
in the context of diabetes, obesity and metabolic syndrome,
one of the primarily occurring phenomena is inflammation.
High peripheral levels of inflammatory biomarkers such as
C-reactive protein (CRP), IL-6 and TNF-α have been described
in obesogenic contexts (Ellulu et al., 2017). Low-grade systemic
inflammation is one of the earliest and main pathological events
that might lead to the development of insulin resistance in most
insulin-sensitive tissues (Kloting and Bluher, 2014; Parimisetty
et al., 2016). The activation of the immune system and chronic
inflammation are not only featured by increased circulating pro-
inflammatory molecules but also by infiltration of macrophages
and other immune cells into the affected tissues.
In the context of obesity, the hypertrophied adipose tissue
experiments a functional switch, changing the secretory profile
of endocrine factors from homeostatic to pathologic or
pro-inflammatory, thereby leading to a decreased metabolic
flexibility (Ronan et al., 2019), with lower levels of the
pro-homeostatic adiponectin and increased levels of pro-
inflammatory adipokines, generating a context of chronic low
grade inflammation affecting not only adipose tissue but also
the liver, insulin-producing pancreatic β-cells, skeletal muscle,
the heart and the brain (Ridker et al., 2000; Aleffi et al., 2005;
Le et al., 2011). Regarding systemic inflammatory markers, a
positive association has been found not only with high BMI and
obesity-related parameters but also with CNS impairment. In
fact, Mac Giollabhui et al. (2020) reported increased levels of the
proinflammatory cytokine IL-6 as a relevant predictor factor of
both depression and executive dysfunction in individuals with
elevated BMI. In fact, chronic sterile, low-grade inflammation
is associated with aging and age-related diseases, leading to the
emergent concept of “inflamm-aging” in order to describe a
dysregulation in the homeostasis of cytokines and oxidative stress
(Franceschi et al., 2018). In the case of AD for instance, there
have been described certain genetic variants leading to increased
levels of IL-1β, IL-6, and TNF-α that are associated with a greater
risk of developing the disease (Wang, 2015; Miwa et al., 2016;
Mun et al., 2016). Circulating levels of these mediators, together
with CRP, constitute relevant damage biomarkers connecting
chronic metabolic diseases such as obesity and T2D with
incident dementia or late-onset AD (Franceschi and Campisi,
2014). Moreover, in preclinical AD models, peripheral immune
challenges with lipopolysaccharides (LPS) or polyI:C have shown
to accelerate or increase Aβ deposition in 3xTg-AD mice and
APPswe Tg2576 (Sheng et al., 2003; Kitazawa et al., 2005; Krstic
et al., 2012), supporting a role for peripheral inflammatory
mediators in brain pathology.
Additionally, in reference to the metabolic-induced
inflammatory response, alterations in gut microbiota have
also emerged critical for pathogenesis. In the last decade,
the gut microbiome has gained increasing interest due to its
role in the physiology of humans and several animal models
including rodents (Bruce-Keller et al., 2009). The composition
and diversity of gut microbiota can be modulated by a wide
range of factors including colonization at birth and lifestyle
events across the lifespan such as feeding behavior, toxins and
antibiotic exposure in addition to aging, experiencing a shift to
a decreased diversity in the elderly and thereby contributing to
systemic inflammation and detrimental signaling to the brain
(Claesson et al., 2012; Bokulich et al., 2016; Sochocka et al., 2019).
For instance, HFD exposure has shown to reduce microbiome
diversity and transplantation of obese-derived microbiota into
control germ-free mice was able to induce metabolic alterations
associated with obesity (Turnbaugh et al., 2006; Cani et al., 2008).
An unhealthy microbiome could promote a “leaky gut” and thus
enable the increase of immunogenic components such as LPS in
plasma, a phenomenon known as endotoxemia, contributing to
the metabolic inflammation (Carvalho et al., 2012). In a similar
fashion, as the gastrointestinal barrier disruption could lead
to the increase of potentially toxic effectors in circulation, the
BBB integrity has also shown to be affected in the context of
metabolic disorders, aging and neurodegeneration (Erickson and
Banks, 2013; Salameh et al., 2019). Therefore, the gut-brain axis
disruption might as well contribute to the negative impact of
peripheral insults on the CNS.
Inflammation in the CNS
Neuroinflammation is a shared hallmark among diverse
pathologies and should not be considered an isolated or
independent phenomenon from systemic inflammation
since different experimental approaches have shown that
peripheral inflammatory challenges as well as chronic low
grade inflammation trigger inflammation in the CNS (Heneka
et al., 2015). In relation to obesity for instance, circulating
pro-inflammatory cytokines, free-fatty acids and ceramides have
shown to impact also on limbic structures. This effect could
be worsened by BBB increased permeability, as it has been
described in HFD exposed rodents, leading to the alteration of
hippocampal function (Hargrave et al., 2016). Hypothalamic
inflammation has been found to be involved in the development
as well as in the maintenance of an obese phenotype, promoting
and perpetuating unhealthy feeding behavior, altering the reward
circuitry (Guillemot-Legris and Muccioli, 2017) and has actually
been acutely detected after high-fat feeding, even before the
establishment of obesity (Maric et al., 2014). In this context,
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reactive gliosis can be found in the arcuate nucleus, being
microglial cells the main cell type proposed to sense nutrient
overload and trigger the inflammatory response since long-chain
fatty acids bind to toll-like receptors (TLR4) and downstream
cytokine synthesis and endoplasmic reticulum stress (ERS)
pathway (Milanski et al., 2009). On the other hand, several
reports have shown that metabolic-induced inflammation is also
present in extra-hypothalamic structures such as hippocampus,
cortex and amygdala, constituting a relevant link between the
neuropsychiatric alterations and obesity or insulin resistance-
associated disorders (Parimisetty et al., 2016; Vinuesa et al., 2016;
Solas et al., 2017).
As regards age-related cognitive decline, neuroinflammation
and oxidative stress are known to be present in the hippocampus
and potentially related to the reduced plasticity and associated
memory impairment (Frank et al., 2006; Patterson, 2015;
Stebbings et al., 2016). Nevertheless, in the particular case of
AD-like aging, it is not yet elucidated if inflammation should
be considered a trigger, consequence or aggravating factor.
Neuroinflammation (mostly given by hyperreactivity of glial
cells secreting pro-inflammatory molecules) is consistently found
in AD patients and animal models (Heneka et al., 2015). In
fact, in the case of animal models, neuroinflammation has
been detected even prior to amyloid deposition (Heneka et al.,
2005; Beauquis et al., 2013). Reactive glial cells and increased
pro-inflammatory mediators have shown to affect both Aβ
production and clearance, two processes directly associated with
the main histopathological hallmark of AD. For instance, acute
neuroinflammation after traumatic brain injury or hypoxia have
shown to increase levels of relevant actors for APP amyloidogenic
enzymatic cleavage such as the beta-site amyloid precursor
protein cleaving enzyme 1 (BACE1), as well as presenilin 1 (PS1)
or nicastrin, components of the γ-secretase complex in rodents
and pigs (Blasko et al., 2004; Chen et al., 2004; Nadler et al.,
2008). Moreover, the deletion of TNF-α in transgenic 5XFAD
mice promoted a decreased deposition of Aβ in association
with a decreased expression of PS1 and β-secretase (Paouri
et al., 2017). Interestingly, Aβ per se acts as an important
TLR4 ligand, constituting a positive feed-forward loop with
neuroinflammation thus contributing to Aβ plaque formation
(Stewart et al., 2010). In reference to Aβ clearance, there are
several mechanisms affected in the context of chronic or unsolved
inflammatory response. Microglial cells, as the first-line defense
brain cells, are mostly in charge of removing Aβ deposits by
phagocytosis and intracellular proteolysis mechanisms such as
proteasome-degradation and autophagy.
During the last decades, several authors emphasized the
relevance of the autophagy-lysosomal system and its regulation
in age-associated diseases like AD, proposing the modulation
of cellular metabolism and the activation of autophagy as a
valid therapeutic approach. Autophagy involves the semi-specific
isolation of intracellular content -mainly misfolded proteins
and dysfunctional organelles- into a double-membrane vesicle
called autophagosome. Later, the autophagosome is fused to
a lysosome, forming the autolysosome, where the content of
the vesicle is degraded and further recycled into the cytosol
(Liu and Li, 2019). Autophagy is negatively affected by age,
and particularly impaired in AD. The impairment of autophagy
involves the accumulation of autophagosomes that do not evolve
into autolysosomes, as it was evidenced in neuronal and glial
cells, both in patients and experimental models of AD (Gregosa
et al., 2019; Uddin et al., 2019; Pomilio et al., 2020; Stavoe
and Holzbaur, 2020). While there is no concluding information
regarding if autophagy impairment is a cause or a consequence
for AD, its dysfunction is related to a loss of amyloid degradation
capacity and an accumulation of toxic waste that could lead to
reduced neuronal viability and neuroinflammation, reinforcing
the degenerative character of this pathology. Chronic activation
of autophagy by rapamycin administration is associated with
cognitive improvement, decreased amyloid pathology and
enhanced autophagy in transgenic mouse models of AD (Spilman
et al., 2010; Majumder et al., 2011). Neuroinflammation is
also associated with this scenario. Our group has recently
shown that microglial autophagy is impaired in AD patients
and experimental models (Pomilio et al., 2020), and that this
condition is associated with the assembly of inflammasomes and
the production of the proinflammatory cytokine IL-1β (Cho
et al., 2014). Interestingly, a recent article by Liu et al. (2020)
showed that promoting microglial autophagy in APP/PS1 mice
using nanoparticles not only enhances amyloid degradation
but also reduces neuroinflammation by causing a decrease
in brain levels of proinflammatory cytokines and an increase
in anti inflammatory cytokines, finally conducing to a better
performance in cognitive tests.
Autophagy in the brain is not independent of peripheral
stimuli. In the last years, several studies showed that gut
microbiota is altered in transgenic mouse models of AD, and that
restoring microbiota enhances the autophagic flux in the brain,
amyloid degradation and cognitive performance (Bonfili et al.,
2017, 2018; Chen et al., 2017). Particularly, Bonfili et al. (2017)
showed that microbiota restoration causes a decrease in plasma
levels of proinflammatory cytokines, suggesting that peripheral
inflammation, brain autophagy and neurodegeneration are
closely related.
Alterations of Insulin Signaling Pathways
Insulin Resistance Triggers
Overall, the canonical function of insulin is to maintain glucose
homeostasis and to regulate cellular division and growth through
the PI3K/Akt pathway and mitogenic activity through the
RAS/MAPK signal transduction pathway. The concept of insulin
resistance emerges when insulin levels, whether elevated or
within normal range, are associated with a diminished metabolic
response or sensitivity (Wilcox, 2005).
Several reports indicate that inflammation affects insulin
signaling pathways in insulin-sensitive tissues (Kloting and
Bluher, 2014; Parimisetty et al., 2016). Hence, it seems evident
that obesity-induced inflammation is closely related to the
development of T2D, mainly featured by an inefficient action
of insulin or insulin resistance, thus placing insulin in the
center of the scene. Among the candidate molecules involved in
this inflammatory response are reactive oxygen species (ROS),
pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and
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stress kinases as Jun N-terminal kinase (JNK), inhibitor of
kappaB kinase (IKK) and protein kinase C (PKC) (Boucher
et al., 2014). Regarding IL-1β, there are relevant factors to
be considered particularly associated with acute and chronic
effects in relation to glycemic control. It has been shown that
postprandial-induced hyperglycemia triggers inflammasome-
mediated maturation and secretion of IL-1β in adipose
macrophages as an homeostatic mechanism to favor insulin-
dependent glucose uptake and protect the organism against
potential food microbes (Dror et al., 2017). Nonetheless, when the
pro-inflammatory cytokine levels together with hyperglycemia-
induced ROS are sustained chronically, deleterious effects arise
and contribute to the development of insulin resistance (Maedler
et al., 2002). The latter has been proposed not only for IL-
1β but other inflammatory cytokines such as TNF-α and IL-6.
Hotamisligil et al. (1993), one of the first groups in assigning
a relevant role for inflammatory cytokines such as TNF-α in
the context of experimental obesity or diabetes, also proposed
that the endoplasmic reticulum (ER) should be considered
as an essential component in the coordination of metabolic
responses (Hotamisligil, 2010; Kloting and Bluher, 2014) and
could also be involved in the disruption of insulin signaling.
Under physiological conditions, proteins are synthesized at the
ER, folded, modified and ultimately targeted to the appropriate
cellular compartment. However, when there is an uncontrolled or
excessive increase in protein synthesis and presence of incorrectly
folded proteins, the ERS response or unfolded protein response
(UPR) is triggered to activate JNK/AP1, IKK, NFκB and oxidative
stress pathways. In the context of metabolic stress, nutrient
overload or elevated free fatty acids constitute potential inductors
of this response (Velloso et al., 2015).
Another relevant phenomenon underlying inflammation-
induced insulin resistance is the activation of TLRs, members
of the pattern recognition receptor family responsible for
the innate immune response. Interestingly, different rodent
models of TLR4 ablation, either genetically modified by
knock-out approaches (Poggi et al., 2007; Jia et al., 2014;
Li et al., 2014) or by pharmacological inhibition (Zhang
et al., 2015), have shown to prevent HFD-induced insulin
resistance. As for TLR4 ligands in obesogenic contexts, it
has been reported that long chain fatty acids increased in
obesity-related contexts are able to stimulate TLR4 signaling
leading to the development of insulin resistance (Velloso
et al., 2015). Regarding lipotoxic stimuli as insulin-resistance
inducers, ceramides have also been found to be very relevant.
Ceramides are important bioactive lipidic messengers regulating
cellular functions such as stress response, inflammation and
survival. Levels are increased in obesogenic and diabetogenic
contexts and were found to induce insulin resistance both
in vitro and in vivo (Holland et al., 2011; Chavez et al., 2014).
Even though ERS and TLRs activation have been originally
studied as independent mechanisms in the pathophysiology
of metabolic disorders, there is a considerable body of
evidence suggesting a constant crosstalk between them in
the modulation of metabolic dysfunction and inflammation
associated to a decreased insulin sensitivity and downstream
actions (Guillemot-Legris and Muccioli, 2017).
During insulin resistance, the activity of Akt -a main effector
of the insulin receptor pathway- remains low. Akt is a multi-
substrate kinase that regulates the activity of the AMP-dependent
kinase (AMPK). Although AMPK is activated by several stimuli,
it acts as a master regulator for cellular metabolism and its
activation is necessary as a mediator for insulin effects on skeletal
muscle and adipose tissue, as it was recently reviewed by Chen
et al. (2020). Particularly, AMPK activation directly inhibits de
novo lipid synthesis and enhances fatty acid oxidation, linking
its activity with insulin resistance and macrophage activation in
the context of obesity and T2D (Herzig and Shaw, 2018). In fact,
activation of AMPK is proposed as the mechanism responsible
for the therapeutic effects of metformin and other antidiabetic
treatments, as it is mentioned ahead in Section “Therapeutic
Approaches.” Akt and AMPK altogether regulate the activity
of the mammalian target of rapamycin (mTOR) complex. The
activation of Akt leads to the activation of mTOR, while
AMPK directly inhibits its function. When activated, mTOR
upregulates major anabolic pathways like protein synthesis while
inhibiting protein degradation through the downregulation of the
autophagic-lysosomal system (Herzig and Shaw, 2018).
Insulin sensitivity, among other factors, is regulated by a
number of small insulin-sensitive adipocytes (Leonardini et al.,
2009), via PPARγ, a member of the peroxisome proliferator-
activated receptors (PPAR) family that regulates the expression
of several genes, mainly related to metabolism and inflammation.
It is highly expressed in adipose tissue, and also in the liver and
skeletal muscle (Vidal-Puig et al., 1996). The endogenous ligands
of PPARs are free fatty acids and eicosanoids, favoring lipid
storage in adipose tissue while reducing lipotoxicity, promoting
an anti-inflammatory response and enhancing insulin sensitivity
(Varga et al., 2011). It has been hypothesized that PPARγ function
is also neuroprotective. It was found to be expressed in the
hippocampus, cortex and hypothalamus and is associated with
decreased levels of pro-inflammatory mediators, ROS and Aβ in
AD models (Inestrosa et al., 2005; Warden et al., 2016).
Insulin Effects on the Brain
Mainly known for its role in peripheral glucose homeostasis,
insulin also has a significant impact within the brain, functioning
as a key neuromodulator in behavioral, cellular, biochemical and
molecular studies. Emerging evidence from human and animal
studies indicate that insulin influences cerebral bioenergetics
and neural functioning (Kellar and Craft, 2020). The brain is
now regarded as an insulin-sensitive organ with widespread,
yet selective, expression of the insulin receptor in the olfactory
bulb, hypothalamus, hippocampus, cerebellum, amygdala and
cerebral cortex. In the hypothalamus, insulin signaling modulates
metabolism, food intake and energy balance (Lee and Mattson,
2014), while in extra-hypothalamic structures such as the
hippocampus, insulin actions are associated with neurotrophic
and neuromodulatory functions. Insulin receptor signaling in
the brain is important for neuronal development, glucose
regulation, feeding behavior, body weight, and cognitive
processes such as executive functioning, learning and memory
(Kellar and Craft, 2020). Insulin receptors are abundantly
expressed in neurons and glial cells (Frolich et al., 1998) and,
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together with insulin-like growth factors (IGFs) and receptors,
regulate functions like neuron differentiation, dendritic growth,
neuronal survival, circuit development, synaptic plasticity and
postsynaptic neurotransmitter receptor trafficking (Kleinridders
et al., 2014; Gralle, 2017), playing a key role in memory and
learning (Blazquez et al., 2014; Ferrario and Reagan, 2017).
Consistently, individuals with diabetes or insulin resistance
show hippocampal atrophy, alterations in brain connectivity and
variable degrees of cognitive impairment, shared phenomena
between metabolic and neurodegenerative disorders (Beauquis
et al., 2008, 2010; Dey et al., 2017).
Insulin signaling has been shown to be impaired in
experimental models of AD (Chua et al., 2012; Ferreira et al.,
2018) and in patients (Baker et al., 2011). Brain insulin resistance
is a cause for dysregulation of brain bioenergetics, and also
leads to enhanced Aβ production, impaired axonal transport,
apoptosis and neuroinflammation, as it was recently reviewed by
Nguyen et al. (2020). Particularly, impaired hippocampal insulin
signaling is associated with impairments in memory and other
executive functions, and it is proposed as a mediator between
peripheral insulin resistance in T2D and brain dysfunction in
AD. In line with this, Li et al. (2018) demonstrated that an
animal model presenting both T2D and AD exhibits accelerated
neurodegeneration and cognitive impairment, in association with
dysregulation of the insulin degrading enzyme (IDE) expression.
IDE is an extracellular protease that degrades not only insulin,
but also Aβ, in a competitive way. Several authors have proposed
that Aβ clearance by IDE could be impaired as IDE is saturated
by the high insulin levels in the extracellular space due to insulin
resistance, finally leading to Aβ accumulation and aggregation
(Qiu and Folstein, 2006; Mayeux and Stern, 2012; Li et al., 2018).
Insulin resistance has also been associated with the
modulation of amyloid production, tau phosphorylation
and neuroinflammation through the regulation of glycogen
synthase kinase (GSK)−3 activity (Jope et al., 2007). This
kinase is one of the main targets of the PI3K/Akt pathway
and is inactive upon phosphorylation by Akt. Hence, it has
been hypothesized that a defect in insulin signaling would lead
to GSK3 activation through diminished PI3K/Akt signaling.
Subsequently, activation of GSK3 would lead to a number
of effects among which tau hyperphosphorylation (Ishiguro
et al., 1993) and increased Aβ production through BACE1
activation (Ly et al., 2013) or APP phosphorylation (Rockenstein
et al., 2007) could play a significant role in AD pathogenesis.
However, there are conflicting results in studies addressing this
issue. While some support this hypothesis (Steen et al., 2005)
others have found that inactive forms of GSK3 are present in
AD brains (Griffin et al., 2005) and this discrepancy would
depend on the progression (early vs. late stages) of the disease
(Jimenez et al., 2011).
It has been shown that insulin resistance, induced by chronic
exposure to a HFD promotes short-term memory impairments
and decreases brain-derived neurotrophic factor (BDNF) and
phospho-Akt levels in the prefrontal cortex and hippocampus.
BDNF, a neurotrophin associated with synaptic and neural
plasticity, shares components of the PI3K/Akt insulin pathway
through the interaction with tropomyosin receptor kinase B
(TrkB) (Kowianski et al., 2018). This fact stresses the relevance
of these signaling cascades’ crosstalk and the consequent impact
of the potential impairment induced by metabolic alterations.
Even though there is a solid body of literature supporting
a mainly pro-homeostatic role of insulin on brain
function, contradicting evidence in relation to aging and
neurodegeneration should not be ignored. Particularly, and
in conflict with the previously mentioned deleterious effects
of insulin resistance, there is evidence from animal models
suggesting that the downregulation of insulin signaling may
have protective effects in aging and AD. In Tg2576 mice, a
commonly used model of AD, neuronal deletion of insulin
receptor substrate 2 (IRS2) is associated with decreased Aβ
deposition in the brain, improved cognitive performance and
increased survival of adult animals (Freude et al., 2009; Stohr
et al., 2013). However, it should be noted that the expression of
Akt and other downstream components of the insulin signaling
pathway are unaffected by the deletion of IRS2 in this model.
Similarly, using the nematode Caenorhabditis elegans expressing
a minigene for human Aβ1−42, Cohen et al. (2006) have shown
that amyloid aggregation is decreased and aging is slowed
when insulin signaling is reduced after a treatment with a daf-2
RNAi. Regarding human studies, Harries et al. (2012) have
shown that the expression of genes participating in insulin
signaling as PI3K, PTEN, FOXO and PDK1 is decreased in aged
human populations in a similar fashion to that seen under the
pro-longevity mTOR inhibition therapy. Thus, these results
may suggest that decreased insulin signaling may have a role
extending lifespan and modulating amyloid aggregation, in
potential conflict with therapeutic strategies aimed at promoting
insulin signaling. However it is not clear yet if the impairment
of insulin signaling is a consequence of neurodegeneration or a
protective response, stressing the need for more mechanistic and
functional studies to clarify this central point.
Alterations of Neural Plasticity
The brain is exposed to a highly dynamic environment and
requires concerted mechanisms to exert appropriate responses.
In that sense, brain plasticity represents the CNS intrinsic
ability to act upon constantly changing conditions by means
of structural and functional processes. Among the phenomena
involved in such flexibility, synapse formation, elimination or
strength modulation, as well as the promotion of hippocampal
neurogenesis are essential mechanisms (Kelly et al., 2006;
Selemon, 2013; Lucassen et al., 2015). In line with this, alterations
of such mechanisms of structural plasticity are associated
with cognitive decline and memory dysfunction in aging and
neurodegenerative disorders.
Adult Hippocampal Neurogenesis
Hippocampal neurogenesis is a key neuroplastic process that
involves the proliferation of neural precursor cells (NPCs) in
the subgranular zone (SGZ), differentiation, survival and proper
integration into the hippocampal circuit. It is a thoroughly
relevant process underlying emotional behavior and cognitive
function mainly associated with memory and learning (Clelland
et al., 2009; Toda and Gage, 2017). Neurogenesis occurs during
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development and continues throughout life, persisting even in
aged adults and AD patients. Nevertheless, it declines with
age and is strongly affected by the environment (Klempin and
Kempermann, 2007). Tobin et al. (2019) recently showed that
adult neurogenesis exhibits a positive correlation with cognitive
status in MCI and AD versus aged patients and could render
an early sign of the disease. Animal models of AD show
decreased rates of hippocampal neurogenesis (Mu and Gage,
2011; Myhre et al., 2019). Interestingly, overactivation of GSK3β
by genetic blockade of the kinase inhibition in NPCs has been
associated with diminished neurogenesis together with impaired
hippocampus-dependent behavior in mice (Eom and Jope, 2009;
Pardo et al., 2016), reinforcing the relevance of neurotrophin-
induced signaling in hippocampal plasticity affected in age-
related neurodegeneration.
Taking into account metabolic disturbances as negative
modulating factors, the aforementioned conditions associated
with obesity and T2D, insulin resistance and sustained
inflammation have consistently shown to promote neural
connectivity dysfunction. Several studies from our group and
others have reported alterations in hippocampal neurogenesis
as a consequence of HFD exposure, occurring in association
with impaired cognitive and emotional processing (Boitard
et al., 2012; Hao et al., 2016; Vinuesa et al., 2016, 2019). In
particular, the early-onset of HFD exposure in rodents has
shown to be especially detrimental; both C57BL6/J mice after
6 (Vinuesa et al., 2019) or 11 (Boitard et al., 2012) weeks of
HFD exposure and 12-week-old rats exposed to a cafeteria diet
(Ferreira et al., 2018), showed a drastic reduction of the total
number of doublecortin (DCX+) cells in the SGZ of the DG.
Besides, hippocampal neurogenesis appears to be affected also in
genetic models of obesity such as the leptin-deficient ob/ob mice,
with alteration of proliferation and differentiation processes in
the SGZ (Bracke et al., 2019). Leptin receptor-deficient db/db
mice, that develop diabetes in addition to obesity, also show a
reduction of neurogenic capability in association to a cognitively
impaired phenotype (Stranahan et al., 2008).
Synaptic Plasticity
As regards structural changes in dendritic spines and synaptic
plasticity upon metabolic disturbances, HFD exposure for
instance has been associated to cause alterations either in
the density or the morphology patterns of dendritic spines
in the hippocampus. Hao et al. (2016) showed that animals
exposed to HFD since 6 weeks of age suffered a decrease
in the density of dendritic spines in dentate granule neurons
in adulthood which was reversible by switching to a low fat
diet. Additionally, work from our group has shown that a
moderate HFD exposure since weaning, was associated with a
predominance of immature dendritic spines in CA1 pyramidal
neurons in young adult C57BL/6 mice, even though the total
density of dendritic spines remained unchanged (Vinuesa et al.,
2019). Moreover, dendritic spine reduction was also detected
in pyramidal neurons of the parietal cortex in the context of
streptozotocin-induced diabetes in hyperglycemic rats, together
with an impaired memory performance assessed by the Morris
Water Maze (MWM) (Malone et al., 2008).
Synaptic failure and loss are key factors underlying cognitive
impairment in AD patients (Scheff et al., 2006, 2015). Progressive
dendritic spine alterations were found to correlate with
intracellular Tau deposits in postmortem analysis (Merino-
Serrais et al., 2013), thereby associating functional and
histological hallmarks of the disease. Several studies have
also shown dendritic spine loss and synaptic dysfunction in
animal models of AD, where Aβ toxicity appears to be the main
contributor (Tu et al., 2014; Subramanian et al., 2020). Apart
from Aβ-induced toxicity, dendritic spine and associated synaptic
alterations could be associated with reduced levels of BDNF
in MCI and AD patients, reinforced by the neuroprotective
effects of the neurotrophin reported in experimental AD models
(Peng et al., 2005; O’Bryant et al., 2009; Caccamo et al., 2010;
Jiao et al., 2016). BDNF signaling through TRKB receptor and
PI3K-Akt-GSK3β pathway are central regulators mediating
synaptic plasticity-required dendritic spine turnover and
preserving long-term potentiation (LTP) (Peineau et al., 2007;
Kowianski et al., 2018). The fact that neurotrophin-induced
regulation shares the main components of insulin pathway and is
counteracted by proinflammatory mediators such as IL-1β (Tong
et al., 2012), stresses the relevance of insulin resistance in AD
pathophysiology.
The fact that the mentioned alterations of structural plasticity
present in AD are also induced by metabolic pathologies would
support a further exacerbation of neuroplasticity decline by
interaction of age-related neurodegeneration with obesity and
associated disturbances.
THERAPEUTIC APPROACHES
Given the relevance of insulin resistance and its close association
with inflammation as common pathophysiological mechanisms
present in metabolic and neurological disorders, in the following
sections we will address the aforementioned phenomena as
potential therapeutic targets for CNS dysfunction in AD-related
pathology. The crosstalk between these pathways on the brain
is schematized in Figure 2, showing the main actors involved
and identifying with letters A-I the potential targets that will be
discussed below, classified as insulin signaling-, inflammation- or
lifestyle-based approaches.
Insulin Signaling-Based Approaches
Among the existing treatments that address insulin resistance
mainly used in diabetic patients, several clinical and pre-
clinical studies have assessed the effect of insulin signaling-based
approaches as potential mitigators of brain dysfunction and
cognitive impairment.
Intranasal Insulin
As it was previously mentioned, the bioavailability and
downstream actions of insulin in the brain can be diminished
in the context of MCI, dementia and particularly in AD,
supporting the concept of the disease as “Type 3 Diabetes.” The
administration of insulin in the context of diabetes is a well-
known treatment. Nevertheless, regarding potentially positive
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FIGURE 2 | Schematic representation of interacting components of the insulin signaling and inflammatory pathways on the brain. Pointed-head arrows depict
activation and blunt-end arrows inhibition, while letter circles A-I point the level at which the potential therapeutic approaches discussed in this article would act.
Treatment definition and corresponding reference section are defined in the inferior square.
neurological outcomes, the systemic administration of insulin
results in low transport levels to the brain and, on the other hand,
may account for undesirable side effects such as hypoglycemia
(Schmid et al., 2018). In that sense, intranasal (IN) insulin
delivery represents a safe and non-invasive method that has
gained increased interest in neurodegeneration research, both
in patients and animal models. Intranasal administration of
insulin has shown a rapid and widespread distribution through
perineural spaces of the trigeminal nerve and the ability to
activate the insulin receptor (Lochhead et al., 2019). The common
doses of IN insulin range from 20 to 160 IU according to different
studies, with different outcomes even though there is a growing
consensus that IN administration is able to promote changes on
CNS as well as peripheral pathways. There are many positive
metabolic effects of IN insulin such as body weight management,
food intake and fat composition, with variations according to
sex, age and protocol of administration (Derkach et al., 2017).
However, in this review we will focus on cognitive-related
outcomes. Several clinical studies, some of which are explicated
in Table 1, have shown that either IN insulin or its long-lasting
analog Detemir were associated with memory improvement
both in cognitively intact (Benedict et al., 2004) and impaired
individuals. Memory amelioration in AD subjects was observed
for different doses of IN insulin and treatment duration with
APOE-ε4 allele being a strong though controversial moderating
factor. Different trials assessing acute (Reger et al., 2008) or
4-month chronic IN insulin treatment (Craft et al., 2017)
showed improved memory outcomes for APOE-ε4 non-carriers,
albeit the latter report also exhibited minor but significant
changes in APOE-ε4 carriers. Contrary to these studies, Claxton
et al. (2015) only detected IN insulin positive modulation of
verbal and visuospatial working memory in AD or MCI adults
carrying APOE-ε4 genetic variant. Additionally, in this cohort
of patients a greater degree of insulin resistance at baseline
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TABLE 1 | Clinical trials targeting insulin resistance and/or inflammation for the treatment of cognitive impairment and AD.
Study Subjects Age Treatment Observations Main outcomes
Insulin signaling- based approaches
Benedict et al. (2004) 38 18–34 8w IN insulin (4 × 40
IU)/day
Healthy subjects Enhanced long-term declarative memory
Better mood rating
Reger et al. (2008) 92 74–77 IN insulin dose (0, 10, 20,
40, or 60 IU)across 5w
MCI, AD subjects Improved verbal memory in APOE ε4- but no APOE
ε4 + MCI and AD adults
Claxton et al. (2015) 60 – 21d IN insulin Detemir (0,
20, 40 IU)
MCI, AD subjects No memory changes with 20 IU
Improved memory in APOE ε4 + but reduced in
APOE ε4- with 40 IU
Craft et al. (2017) 36 60–80 4m IN insulin or Detemir (0,
40 IU)
MCI to moderate AD
subjects
Improved delayed memory composite scores for
regular insulin compared to placebo
Greater improvement in insulin treated APOE ε4
non-carriers
No memory changes with Detemir
Gejl et al. (2016) 38 50–80 26w GLP1-RA liraglutide AD patients No significant differences in cognitive scores or Aβ
levels
Improved cerebral glucose metabolism
Mullins et al. (2019) 27 71–74 18m GLP1-RA exenatide MCI/early AD (early
terminated trial)
Reduced BMI and improved glucose tolerance;
No significant differences in cognitive test or AD
CSF biomarkers;
Reduced Aβ1−42 in neuronal-derived plasma EVs
Koo et al. (2019) 732 ≥60 Metformin Non-diabetic and diabetic
subjects
Association of metformin with rapid cognitive
deterioration
Koenig et al. (2017) 20 55–80 8w metformin/placebo Non-diabetic MCI/early AD Improvement in executive function, with a trend in
amelioration of learning and memory
No changes in CSF levels of Aβ, Tau or pTau
Luchsinger et al. (2016) 80 55–90 12m metformin/placebo Non-diabetic,
overweight/obese, MCI
patients
Decreased inflammatory marker CRP
Improved scores in total recall tests
No changes in plasma levels of Aβ-42
Ryan et al. (2006) 141 43–75 Metformin monotherapy +
rosiglitazone/glyburide
T2D patients Improved working memory, no changes in learning
ability or mood
Improved blood glucose with both drugs
Decreased CRP and fasting insulin with
rosiglitazone
Sato et al. (2011) 42 77 6m Pioglitazone Mild AD patients with T2D Improved scores in MMSE, ADAS-J-cog, and
WMS-R logical memory-I
Improved rCBF and insulin sensitivity
Watson et al. (2005) 30 55–85 6m Rosiglitazone Mild-to-moderate cognitive
impaired patients
Improved delayed recall and selective attention
Decreased plasma Aβ levels in the placebo group
but no changes with RSG




No effect of RSG but interaction with APOε-4
genotype,
with an improvement in the ADAS-cog of APOε-4
positive patients
Gold et al. (2010) 693 24w placebo/2 or 8 mg
RSG XR/10 mg donepezil
Mild-to-moderate AD
patients
No significant differences in cognitive outcome or
Aβ levels
Inflammation- based approaches
Larsen et al. (2007) 70 50–70 Anakinra (IL1β receptor
antagonist)
T2D patients Decreased glycemia and β cell function
Decreased CRP and IL6
Cavelti-Weder et al.
(2012)
98 34–70 Gevokizumab T2D patients Improved glycemia and reduced systemic
inflammation




No changes in ADAS-Cog scores




No effect on cognitive decline
Less cognitive worsening in APOE-ε4 carriers than
APOE-ε4 non-carriers
(Continued)
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TABLE 1 | Continued
Study Subjects Age Treatment Observations Main outcomes
Non-pharmacological lifestyle approaches
Hoffmann et al. (2016) 200 50–90 16w–60 min moderate-to-high
PA x3/w or control
Mild-to-moderate
AD patients
Less severe neuropsychiatric symptoms in
intervention group
Potential cognitive improvement in high-intensity
maintenance group
Jensen et al. (2019) 200 50–90 16w–60 min moderate-to-high
PA x3/w or control
Mild-to-moderate
AD patients
Increased sTREM2 in exercise group CSF and IL6
in plasma
Reduced plasma IFNγ in control vs. exercise
APOE-ε4 carriers
Sobol et al. (2018) 49 69 (52–83) 16w–60 min moderate-to-high
PA x3/w or control
Mild-to-moderate
AD patients
Increased cardiorespiratory capacity (VO2 peak)
Positive association of VO2 peak with cognitive and
neuropsychiatric symptoms
Napoli et al. (2014) 107 ≥65 52wPA, diet or both and control Obese and
sedentary patients
Weight loss and exercise positively associated with
improved scores in cognitive status







Quinn et al. (2010) 402 76 (9.3) 18m DHA Mild-to-moderate
AD patients




174 76 (9) 6–12m DHA and EPA Mild-to-moderate
AD patients
Positive effect in cognitive decline rate only in small
subgroup with very-mild AD
Shinto et al. (2014) 34 >55 12mDHA and EPA Probable AD
patients
Decrease decline in MMSE score
Eriksdotter et al. (2015) 174 6m DHA and EPA Mild-to-moderate
AD patients
Inverse association between omega 3 seric PUFAs
and cognitive deterioration rate




Improved ADAS-cog scores in APOE-ε4
non-carriers





Improved ADAS-cog scores in KD group
Henderson et al. (2009) 152 51–93 (76.8) Ketogenic compound AC-1202 Mild-to-moderate
AD patients
No overall cognitive changes, improvement in
APOE ε4 non-carriers
Tamtaji et al. (2019) 79 (77.8) 55–100 12w
probiotics+ selenium/selenium/
placebo
AD patients Probiotics + selenium group exhibited improved
MMSE scores than placebo or Selenium only
Kobayashi et al.
(2019a)
27 82.5 (5.3) 24w Bifidobacterium breve A1 MCI elder patients Improved cognitive and mood scores
Kobayashi et al. (2019) 117 61.6 (6.83) 12w Bifidobacterium breve A1 MCI elder patients Improved scores at neuropsychological tests
was associated with greater cognitive improvement after the
treatment (Claxton et al., 2015).
As regards animal models, IN insulin treatment has been
associated with positive results in the behavioral profile,
brain metabolic pathways, neuroinflammation and plasticity
of several rodent models of AD-like aging. For instance, 4-
to 5-month-old APP/PS1 transgenic mice treated with IN
insulin for 6 weeks presented enhanced memory performance
and decreased anxiety-like behavior, along with improved
histopathological signs such as decreased levels of soluble
Aβ and Aβ plaques in the hippocampus and cortex, insulin-
signaling rescue and enhanced hippocampal neurogenesis in
relation to vehicle-treated mice (Mao et al., 2016). Moreover,
IN insulin treatment has shown beneficial effects in the non-
transgenic model SAMP8 AD-like mice. Twelve-month-old
AD-like mice exhibited cognitive improvement assessed by
spatial memory and object recognition paradigms (Salameh
et al., 2015). The same insulin dose rendered hippocampal
gene expression changes associated with the inflammatory
response in young and aged SAMP8 mice (Rhea et al.,
2019). Consistent with this, IN insulin treatment exhibited
a positive cognitive, metabolic and histopathological outcome
in 14-month-old HFD-induced 3xTG-AD mice (Sanguinetti
et al., 2019). Furthermore, in the intracerebroventricular (i.c.v)
streptozotocin-induced model, claimed by several authors to
promote an AD-like phenotype, IN insulin has shown to prevent
memory impairment, neuroinflammation and insulin resistance
in the hippocampus and cortex (Rajasekar et al., 2017a), as well
as promoting restored cerebral blood flow (CBF), decreased ROS
and increased BDNF expression (Rajasekar et al., 2017b).
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Glucagon-Like Peptide 1 Receptor Analogs
(GLP-1 RAs)
Glucagon-like peptide 1 is a peptide hormone mainly synthesized
in intestinal L-cells and is one of the incretin hormones
promoting glucose-induced insulin secretion by the pancreas
after food intake, reducing the release of glucagon and also
protecting the pancreas by preventing apoptosis of β-cells (Farilla
et al., 2003; de Heer et al., 2008). Apart from these effects, it
has been shown that this hormone plays an important role in
different organs. For instance, GLP-1 receptors are also present
in the liver, heart and brain. GLP-1 function has been associated
to the prevention of cardiovascular diseases (Bethel et al., 2018)
and constitutes a key component of the gut-brain axis, behaving
as a relevant neuropeptide, not only for the regulation of
food intake and glucose homeostasis but as a neuroprotective
factor in relation to synaptic function and plasticity (Gault
and Holscher, 2008). As regards T2D and obesity treatment,
there are currently approved GLP-1 RAs such as exenatide,
liraglutide and lixisenatide which are resistant to the enzymatic
cleavage of dipeptidyl peptidase-4 (DPP-4), thus accounting
for an increased half-life in comparison to endogenous GLP-
1, that have shown positive management of the disease (Aroda,
2018). Given the pleiotropic character of GLP-1 R and in
particular its role in neuromodulation and associated cognitive-
related outcome, the use of GLP-1 RAs has been proposed as
a potential therapy for neurodegenerative diseases (Gejl et al.,
2016). Interestingly, Parkinson’s disease patients that participated
in a randomized controlled trial (RCT) for exenatide exhibited
improved motor and cognitive scores 12 months after the trial
endpoint (Aviles-Olmos et al., 2014).
Although there is an important research gap regarding clinical
evidence in AD given the limitation of sample size or unfinished
trials (Mullins et al., 2019), as it is shown in Table 1 for the
GLP-1RAs exenatide and liraglutide, there is very promising data
drawn mainly from preclinical animal models of AD.
In that sense, Cai et al. (2018) showed that the GLP-1 RA
lixisenatide treatment for 60 days in 12-month-old APP/PS1/Tau
AD female mice promoted a decreased Aβ plaque load and
p-Tau levels in the hippocampus, along with a decreased
neuroinflammatory status. In a previous work, the same group
also showed the ability of lixisenatide to ameliorate memory
performance assessed by the MWM in intrahippocampal Aβ-
injected rats (Cai et al., 2014). Regarding exenatide and cognitive
outcome in AD rodent models, its use has been associated to
memory improvement in i.c.v streptozotocin (STZ)-induced rats
when treated during 2 weeks (Solmaz et al., 2015) and Bomba
et al. (2013) showed that 3-month-old PS1-KI mice treated for
9 months with the GLP-1RA had improved performance in
MWM while the 3xTg-AD assessed within the same protocol, did
not show cognitive amelioration. Despite the lack of cognitive
improvement in 3xTg-AD mice, the authors later showed that
exenatide promoted an enhanced BDNF signaling and reduced
inflammation in HFD-induced 3xTg-AD mice (Bomba et al.,
2019). Moreover, Batista et al. (2018) have recently reported
neuroprotective features of liraglutide not only in mice i.c.v-
injected with Aβ oligomers (AβO) but also in non-human
primates (NHP). Interestingly, the GLP-1 RA was able to revert
AβO-induced cognitive impairment as well as to prevent insulin
receptor loss in mice hippocampus, the latter also being found
in NHP, along with synapse loss prevention and decreased p-Tau
levels (Batista et al., 2018). Finally, a dual therapy targeting
both GLP-1 and GIP incretin receptors, proposed as improved
candidates for T2D treatment, has shown to ameliorate memory
impairment, Aβ deposition, glial reactivity and expression
of synaptic marker PSD95 in 10-month-old APP/PS1 mice,
potentially due to the rescue of proteostatic functions associated
to the enhancement of autophagy and decreased ERS response
(Panagaki et al., 2018).
Metformin
Metformin constitutes one of the most common treatments for
T2D. It is an oral biguanide and anti-hyperglycemic drug that acts
as an insulin sensitizer, lowering blood glucose by increasing its
uptake and reducing hepatic gluconeogenesis (Zhou et al., 2001).
Although metformin’s mechanism of action is not thoroughly
understood, it has been associated with the activation of Ampk.
The use of metformin in diabetic patients has been associated
not only with blood glucose control but also with an improved
lipidic profile and decreased inflammatory markers (Lin et al.,
2018). Concerning the impact of metformin in cognitive decline,
either induced in the context of diabetes or among age-related
AD patients, there is promising evidence albeit contradictory
data should be also taken into account. In Table 1, we can
find a representative selection of clinical studies addressing
brain-related outcomes of metformin treatment in aged patients
with/without diabetic medical history. For instance, in a pilot
study, Koenig et al. (2017) showed that metformin exposure
in non-diabetic patients with MCI or early signs of AD was
associated with an ameliorated cognitive function, even though
no changes in AD CSF biomarkers such as Aβ, Tau or p-Tau levels
were observed. Moreover, in non-diabetic patients with amnestic
MCI co-occurring with overweight or obesity, metformin
appeared to ameliorate systemic inflammation lowering CRP
levels and a partial improvement in recall memory (Luchsinger
et al., 2016). However, in a prospective cohort report with
a 1–7.6 years range follow-up, comparing older non-diabetic
patients and diabetic patients treated or not with metformin,
the exposure to the biguanide drug was not associated with
changes in Ad assessment as shown by the Korean version of
the Consortium to Establish a Registry for Alzheimer’s Disease
Assessment Packet (Cerad-K), the short geriatric depression scale
(SGDS) or activities of daily living score (Barthel ADL index). In
fact, when analyzing annual “rapid deterioration” among diabetic
patients, the authors found metformin to be associated with
a more marked deterioration (Koo et al., 2019). Nonetheless,
more longitudinal and larger cohort studies should be assessed
since there are confounding factors such as other antidiabetic
treatments and lifestyle factors (diet and exercise), that may
account for the variability and conclusions of such complex
studies.
Concerning experimental assessment of metformin in animal
models, the use of the anti-hyperglycemic drug has shown
to rescue hippocampal plasticity alterations and associated
cognitive outcomes in both metabolic dysfunction-induced
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and AD-like paradigms. As an example, oral administration
of metformin in middle-aged C57BL/6J mice was able to
rescue spatial memory impairment, adult neurogenesis in the
DG, presumably by the enhanced signaling of IR/IRS1 and
AMPK/PKC detected in the hippocampus of metformin chronic
exposure (Tanokashira et al., 2018). In the same line, db/db mice
exposed to metformin exhibited an improved spatial memory
assessed by the MWM and a lesser degree of hippocampal
atrophy (Chen et al., 2019). In the context of experimental
AD, 26-week-old APP/PS1 female mice were treated during
14 days with i.p metformin and several pathophysiological
parameters were changed. Along with hippocampus-dependent
memory improvement, metformin exposure in APP/PS1 mice
was associated with an increased neurogenic ability, reduced
Aβ soluble levels and deposits as well as an amelioration of
the inflammatory status in hippocampus and cortex, in relation
to vehicle-treated APP/PS1 mice. As regards the potential
mechanisms involved, the authors showed the relevance of the
reported induction of AMPK/mTOR/PKC pathway since at least
the inflammatory response and soluble Aβ levels decreased by
metformin in the hippocampus and cortex of APP/PS1 mice
was impaired in the presence of AMPK inhibitor (Ou et al.,
2018). Interestingly, in a sporadic AD model, 12-month-old
SAMP8 mice treated with metformin for 8 weeks, also exhibited
an ameliorated behavioral profile with improved learning and
memory parameters together with decreased levels of Aβ and
p-Tau, even though pGSK3β was found to be slightly increased
(Farr et al., 2019).
PPAR Agonists
Among insulin sensitizing drugs, another relevant category is
represented by thiazolidinediones such as rosiglitazone (RSG)
and pioglitazone (PIO). Such compounds, commonly used in
the management of T2D, are agonists/ligands of PPARγ receptor,
a master regulator of adipose tissue differentiation. As regards
clinical evidence of pharmacological ligands of PPARγ, several
reports addressed the impact of glitazones on the cognitive
status of patients with diabetes and/or MCI-AD (Table 1).
Ryan et al. (2006) analyzed diabetic patients with metformin
monotherapy that were exposed during 24 weeks to RSG or
glyburide treatment. In the metabolic sphere, both drugs were
able to improve blood glucose and fasting insulin levels and
C-peptide were only reduced in the rosiglitazone group. Both
drugs were associated with improved working memory, even
though no differences were registered in learning ability or mood
assessment (Ryan et al., 2006). Concerning T2D patients co-
occurring with mild AD, antidiabetic add-on therapy with PIO
for 6 months enhanced insulin sensitivity, improved patients
performance in the following cognitive tests: Mini- Mental
State Examination (MMSE), Alzheimer’s Disease Assessment
Scale- Cognitive Subscale Japanese version (ADAS-J-Cog), and
Wechsler Memory Scale-revised (WMS-R) logical memory-I and
regional CBF in the parietal lobe (Sato et al., 2011). The effect of
RSG in AD patients is rather controversial yet. Although certain
preliminary or explorative analyses showed an association with
cognitive improvement (Watson et al., 2005) or an interaction
of the treatment with APOE-ε4 genotype (Risner et al., 2006),
this was not further supported by Gold et al. (2010) in their large
clinical study and future clinical evidence is needed.
In relation to experimental data from animal models and
potential mechanisms involved, PPAR agonists have shown
positive effects in AD pathophysiology and cognitive status.
For instance, the treatment of 3xTG-AD female mice with
PIO was associated with several beneficial effects such as
learning improvement, decreased Aβ and Tau deposits in the
hippocampus and enhanced hippocampal plasticity shown by
increased LTP, along with decreased plasma cholesterol levels
(Searcy et al., 2012). Neuroprotective outcomes in AD models
were also found by combining different PPAR agonists. For
example, the use of PPAR-δ and PPAR-γ agonists L165,041
and F-L-Leu, respectively, has shown positive changes in brain
slices from i.c.v STZ injected rats: decreased inflammation,
improved mitochondrial function and reduced Aβ neurotoxicity,
although lipid peroxidation and cholinergic function were not
rescued (Reich et al., 2018), suggesting that PPAR ligand
therapies should be thought as complementary treatments in
AD-like pathology. In the same line, a recent report showed
that targeting PPAR-α with fenofibrate and PPAR-γ with PIO
during 21 days ameliorated memory impairment induced by
Aβ1−40 i.c.v injection. Additionally, authors found the Wnt/β
catenin to be enhanced with the treatment, proposing this
signaling pathway relevant for neuron plasticity and synaptic
remodeling altered in AD and mood disorders to be involved
(Assaf et al., 2020).
Inflammation-Based Approaches
As mentioned in previous sections, inflammation is a crucial
phenomenon in the development of insulin resistance-
related pathologies and targeting different components of
the inflammatory response has been a promising yet challenging
approach in chronic metabolic pathologies such as obesity
and diabetes. Furthermore, taking into consideration that
inflammation is a common factor occurring also in a wide
variety of neuropsychiatric pathologies, and with microglia
being a fundamental element in such response, many authors
have undertaken experimental animal approaches to inhibit
inflammation and ultimately microglial cells with the aim to
reverse cognitive decline. In the present section, we will analyze
available inflammation-based therapies used in diabetes or
obesity and the impact as potential treatment for AD.
TLR4 and Cytokine-Signaling Targeting
As it was previously described, inflammatory mediators are
intimately related to the promotion and propagation of
metabolic-induced damage in insulin-resistant contexts both in
the periphery and the CNS. Even though anti-inflammatory
therapies are not primary treatments for diabetes, obesity or AD,
there is interesting clinical and preclinical evidence that may as
well contribute to strengthen the role of inflammation and enable
the design of future strategies.
As regards TLR4 direct targeting, neurological available data
is scarce and comes mostly from animal models possibly due to
its relevance in innate immunity and potential secondary effects.
Moser et al. (2018) showed that in pathologic contexts such as
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diet-induced obesity, pharmacological microglia TLR4 inhibition
with TAK-242 prevented adverse neurological outcomes by
decreasing microgliosis, enhancing neurogenesis and potentially
modifying amyloidogenic pathways. Consistent with this, the
neutralization of HMGB1, a TLR4 ligand has shown to reverse
cognitive decline and brain pathology in the 5xFAD mouse
model. The subcutaneous administration of HMGB1 monoclonal
antibody was able to recover dendritic spine density and decrease
DNA damage in 6-month-old 5xFAD cortex (Fujita et al., 2016).
In the same line, inhibiting obesity-induced microglia activation
has shown to ameliorate cognitive decline in two different
approaches: pharmacologically with the use of minocycline
and genetically by the downregulation of microglial fractalkine
receptor (Cope et al., 2018). Accordingly, in a very recent report,
Melo et al. (2020) showed that targeting microglia inflammation
induced by the exposure to the saturated fatty acid palmitate
prevented both the defective insulin signaling in hippocampal
cultures and also in rodents, in addition to amelioration of the
cognitively impaired phenotype. This was achieved by the use
of two different approaches: minocycline or TNFα- neutralizing
antibody therapy with infliximab. The latter also prevented
memory impairment in mice exposed to chronic HFD feeding
(Melo et al., 2020), reinforcing the role of pro-inflammatory
cytokines as mediators of metabolic-induced impairment of
hippocampal flexibility, as it will be further discussed.
In relation to TLR4 downstream signaling, there is an
increasing body of literature addressing NFκB induced-cytokines
targeting. One of the most studied is IL-1β due to its close
association with metabolic inflammation and insulin resistance.
IL-1β receptor antagonists (IL-1β RA) have been used in clinical
trials focused both on diabetic and AD-like scenarios as it
can be seen in Table 1. For instance, T2D adult patients
treated with the IL-1β RA anakinra presented ameliorated
glucose levels and pancreatic function with decreased systemic
inflammation markers such as CRP and IL6 (Larsen et al.,
2007) and similar results were observed with the use of IL-
1β neutralizing antibody Gevokizumab (Cavelti-Weder et al.,
2012). As regards the impact of cytokine inhibition in cognitive
decline and AD pathology, evidence comes mostly from animal
models. APP/PS1 mice lacking either NLRP3 or caspase 1,
which are key components for the maturation and secretion
of IL-1β, showed improved spatial memory, synaptic plasticity
and decreased Aβ levels (Heneka et al., 2013), suggesting a
relevant role of the pro-inflammatory cytokine in the progression
of AD pathology. In the same line, LTP analysis in a rat
model of amyloidosis (McGill-RThy1- APP TG rat) showed
improved synaptic plasticity when animals were treated with
NLRP3 inhibitor Mcc950, IL-1β RA anakinra or anti- TNF-α
(etanercept) (Qi et al., 2018). TNF-α is also one of the
most relevant pro-inflammatory cytokines and its neutralization
has been associated with improved cognition and synaptic
flexibility in different AD models. XPro 1595 anti- TNF-α
antibody rescued LTP, Aβ deposition and inflammatory response
in 5xFAD (MacPherson et al., 2017) and the neutralization
TNFSF10 pro-apoptotic cytokine belonging to TNF family
was also able to improve spatial memory, decrease Aβ levels
and inflammation in the hippocampus of 3xTG-AD mice
(Cantarella et al., 2015). Interestingly, XPro 1595 anti- TNF-
α antibody also exhibited interesting results in a diet-induced
obesity paradigm by exposing C57BL/6 mice to a high-
fat high-carbohydrate diet. Authors have recently found not
only an improvement of metabolic parameters associated to
dyslipidemia and insulin resistance in the periphery but also
central insulin signaling was improved in the hypothalamus and
prefrontal cortex, together with behavioral changes in anxiety-
like behavior (De Sousa Rodrigues et al., 2019), reinforcing the
potential of anti-inflammatory strategies in metabolic- and brain-
dysfunction contexts.
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs (NSAIDs) constitute
a well-known strategy for targeting both acute and chronic
inflammation in diverse contexts. There are different types of
compounds in this category with primarily anti-inflammatory
and analgesic consequences, associated with the inhibition of
cyclooxygenase (COX) activity and downstream prostaglandin
synthesis (Rao and Knaus, 2008). Given the relevance of the
inflammatory response in the pathophysiology and progression
of chronic metabolic diseases such as obesity and T2D as
well as in the context of AD-like dementia, there has been
a genuine interest in preclinical and clinical exploration of
NSAIDs as potential therapies. However, there is controversial
or insufficient data as regards their efficacy. In relation to AD
risk and progression, there is observational data suggesting a
potential benefit of NSAIDs usage in the prevention of the disease
(Etminan et al., 2003) and small clinical trials providing evidence
in the same line (Rogers et al., 1993), albeit further RCTs should
be conducted. For instance, in a quite large multicenter RCT,
Aisen et al. (2003) showed that the selective Cox-2 inhibitor
rofecoxib or traditional NSAID naproxen failed to ameliorate
cognitive decline after 12-month exposure to the drugs in mild-
to-moderate AD patients. Additionally, drug-exposed groups
reported adverse effects such as dizziness, hypertension and
fatigue more frequently than placebo (Aisen et al., 2003).
Consistent with this work, 12-month exposure to ibuprofen
was also unable to slow time-dependent cognitive decline, even
though an interestingly favorable different outcome was seen for
APOE-ε4 carriers in comparison with non-carriers (Pasqualetti
et al., 2009). In the same line, the large longitudinal trial
assessing naproxen or celecoxib NSAIDs contributed to the “non-
beneficial” body of evidence of these drugs for improvement of
AD cognitive impairment (Group et al., 2008).
Despite the predominance of disappointing clinic results,
animal models of AD have shown positive effects of NSAIDs in
the progression of the disease. For example, ibuprofen treatment
was associated to decreased Aβ deposition, microglial activation
and inflammatory cytokine levels in the APP Tg2576 AD mice
model, together with improved signs of degeneration shown by
decreased dystrophic neurites (Lim et al., 2000; Yan et al., 2003).
Likewise, decreased microglial activation and Aβ deposition was
observed in 12-month-old APP/PS1 transgenic mice treated with
the NCX-2216 NSAID agent (Jantzen et al., 2002). Moreover,
and in relation to diabetes and cognitive impairment, Wang
et al. (2011) showed that aspirin treatment during 4 and 8 weeks
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promoted decreased levels of pro-inflammatory cytokines in
the hippocampus and improved spatial memory in STZ-
induced diabetic mice.
Liver X Receptor (LXR) Agonists and Cholesterol
Targeting
As mentioned, cholesterol and its oxidized forms called
oxysterols are associated with increased risk for AD, promotion
of amyloid pathology and induced inflammation. Oxysterols
are ligands for liver X receptors (LXRs), nuclear receptors that
function as lipid-activated transcription factors and regulate
cholesterol homeostasis (Wang and Tontonoz, 2018). Besides
their role on lipid metabolism, LXRs can regulate inflammation
and neuroinflammation. Evidence from in vitro models showed
that LXR agonists inhibit the production of pro-inflammatory
mediators from microglia and astroglia at least in part through
interfering with the capacity of NFκB to bind DNA and
induce transcription (Zhang-Gandhi and Drew, 2007). Also
LXR agonists can interfere with Aβ production and decrease
soluble amyloid peptides in the brain of the APP23 mouse
model of AD (Koldamova et al., 2005). Some drug candidates
have been proposed for AD treatment but due to the mixed
nature of LXRs effects and adverse effects such as dyslipidemia
and hepatic steatosis (Grefhorst et al., 2002; Tai et al., 2014),
clinical translation of these strategies has been unsuccessful.
Novel agonists overcoming these effects can have potential
as AD therapies.
A more direct approach has been proposed using statins
and cholesterol lowering therapies. First known for their
protective effects on cardiovascular disease, statins were then
proposed as risk-reducing therapies for AD, with many
studies describing protection against the risk of dementia and
AD but failing when tested in controlled randomized trials,
probably due to the complexity of AD, to the variety of
lipids involved (HDL cholesterol, LDL-cholesterol, triglycerides)
and the separate cholesterol pools (circulation vs. brain) that
coexist (reviewed in Reitz, 2013; Samant and Gupta, 2021).
Another strategy aims at enhancing CYP46A1 activity, the
enzyme that converts cholesterol to 24S-hydroxycholesterol
(24S-OHC), the major oxysterol in the brain. This oxysterol,
besides its effects on cholesterol metabolism and function as
LXR agonist, is an α-secretase activator that hence decreases
the rate of Aβ production and plaque formation (Bjorkhem
et al., 2009). Efavirenz, L-glutamine and dapagliflozin are some
of the CYP46A1 activators that showed promising results in
experimental models and are being tested in clinical trials (Mast
et al., 2017; van der Kant et al., 2019; Samant and Gupta, 2021).
Non-pharmacological Lifestyle
Approaches
As it can be appreciated in the previous sections, on
a general basis insulin function-based therapies appear to
downregulate inflammation and inflammation-based therapies
seem to improve insulin sensitivity, supporting the notion of
inflammation and insulin resistance as bidirectionally affecting
phenomena. In that line, in the present section we will discuss
non-pharmacological lifestyle approaches mainly associated to
diet and physical activity interventions in aged adults either
with obesity comorbidity or age-related cognitive impairment.
Interestingly, such approaches can be potentially proposed not
only as treatments but also as relevant preventive strategies in
order to promote a healthier aging and improved quality of life.
Physical Activity (PA)
Among lifestyle modifiable risk factors associated with AD, great
attention has been devoted to physical activity since sedentarism
is a crucial risk factor for obesity, cardiovascular disease and
is also associated with impaired cognitive function. Sustained
physical activity has shown to ameliorate overall health and
particularly maintain cognitive function in disease-free elders
even when taken up at late stages (Elosua et al., 2005; Hamer
et al., 2014). Moreover, non-demented patients with physical
and cognitive frailty exhibited positive results regarding both
physical parameters such as muscle strength and speed and
also in cognitive flexibility when exposed to a 4 months high-
speed resistance exercise training (Yoon et al., 2018). Given
the lack of successful therapies for age-related dementia, and
in particular due to AD, several clinical trials have addressed
exercise-based interventions as a potential treatment of AD
symptoms, some of which are cited in Table 1. For instance,
a RCT assessing the impact of high-to-moderate exercise in
patients diagnosed with probable mild or moderate AD has
shown to improve neuropsychiatric symptoms and cognitive
status after 16 weeks of continuous attendance to the program
(Hoffmann et al., 2016). From the same trial, Jensen et al. (2019)
recently reported the effect of the intervention on inflammatory
biomarkers. Although they did not find many significant changes,
the exercise group presented increased CSF levels of sTREM2
and IL-6 in plasma and, interestingly, APOE-ε4 non-carriers
had reduced levels of IFNγ than APOE-ε4 carriers after exercise
intervention (Jensen et al., 2019). A subgroup of the patients
enrolled in the trial were subjected to cardiorespiratory fitness
assessment and an improvement was found in the intervention
group, together with a positive association with mood and
cognitive outcomes (Sobol et al., 2018). In close association with
the physical activity approach, dance therapy constitutes a non-
pharmacological alternative that has exhibited positive outcomes
in the amelioration of several symptoms related to AD pathology.
Exposure to different types of dance sessions has shown to
promote improvement in diverse domains including physical
well-being, mood and cognitive status, irrespective of the practice
duration (Lazarou et al., 2017; Marquez et al., 2017). However,
it should be noted that this kind of intervention not only
entails moderate exercise but also social interaction. Therefore,
the improvement assessed would be the result of mixed stimuli
resembling an enriched sensory-motor environment, as proposed
by Kattenstroth et al. (2010).
In reference to the interaction with obesity or insulin
resistance in the older population, lifestyle interventions also
showed to ameliorate cognitive function. Even though the
impact of weight loss in the elderly is controversial, in the
case of obese older patients, weight loss associated to diet
and exercise has shown positive outcomes in several measures
assessing global cognition. In fact, the combination of both
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interventions appeared to be better, although for several
parameters the combination of diet and exercise was no different
than exercise alone (Napoli et al., 2014). Additionally, albeit being
a rather small sample-sized study, a light exercise intervention
promoted mild improvement in executive functioning in non-
demented T2D patients with self-reported cognitive impairment
(Shellington et al., 2018).
Regarding experimental models, there is an extensive body
of literature addressing the impact of exercise paradigms on
brain function (Ryan and Kelly, 2016). Exercise has elicited
positive effects on cognition, brain metabolism and plasticity.
For instance, 6-month-old APP/PS1 mice subjected to regular
exercise during 4 weeks exhibited improved learning and spatial
memory together with decreased levels of Aβ and p-Tau
in the cortex and hippocampus. Additionally, it promoted
enhanced mitochondrial function and increased synaptic density
(Pang et al., 2019). Likewise, it was recently reported that
hippocampus-dependent memory and synaptic puncta were
positively modulated in 12-month-old mice of the same strain
subjected to running during 4 months (Zhang et al., 2020).
Furthermore, running in the 5xFAD mice promoted beneficial
effects in spatial memory and Aβ burden along with increased
BDNF levels and enhanced adult neurogenesis. Interestingly
enough, these effects were partially mimicked by the combination
of adult neurogenesis enhancement via NPCs’ pharmacologically
induced survival and BDNF overexpression in the hippocampus.
These effects were not detected when neurogenesis alone was
stimulated, suggesting a crucial role for BDNF in the exercise-
induced response (Choi et al., 2018). Moreover, exercise has also
shown to ameliorate hippocampus-dependent behavior, together
with inflammation and oxidative stress in the “sporadic” rat
model of AD induced with SZT (Lu et al., 2017). Finally, exercise
has also promoted pro-cognitive, pro-neuroplastic and anti-
inflammatory effects in metabolically challenged contexts such
as diabetes or diet-induced obesity (Ruegsegger et al., 2019;
Wang et al., 2019), becoming a quite strongly recommendable
lifestyle approach not only to prevent the development of the
mentioned chronic disorders but also being potential therapies
in the amelioration of life quality by targeting inflammation and
insulin resistance derangements.
Diet
In the same sense that highly processed fat and sugar-enriched
western diets negatively affect metabolism, inflammatory status
and cognitive function, modulating dietary composition can be
a powerful strategy to positively modify the aforementioned
health domains. For instance, Mediterranean diet (MD) has
been associated with general wellbeing and preserved cognitive
function in the elderly (McGrattan et al., 2019). MD is
predominantly constituted by fruits, vegetables, wholegrains and
legumes, fish and poultry to a lesser extent and a very low
intake of red meats and processed food where olive oil is the
main source of fat, thereby associated with antioxidant and
anti-inflammatory components. Although MD has exhibited an
important adherence among commonly proposed diets, the use
of certain supplements addressing some of its components has
also been related to beneficial effects. As an example, lycopene is
a potent antioxidant carotenoid present in fruits and vegetables
that has shown protective effects in several chronic diseases such
as cancer, cardiovascular disease and neurodegeneration (Saini
et al., 2020). As regards dietary interventions, CNS impact of lipid
metabolism-based supplements was given attention. Not only
approaches to decrease cholesterol levels were studied (Chu et al.,
2018) but also administration of fish oil or similar supplements
containing omega3 polyunsaturated fatty acids (PUFAs) for their
potentiality to maintain cognitive function. The most commonly
used PUFAs are docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA), and alpha-linolenic acid (ALA), which are reported as
relevant precursors of neuronal membrane components, fluidity
and signaling (Chappus-McCendie et al., 2019). As it can be
appreciated in Table 1, several clinical trials analyzed the impact
of DHA and EPA in patients with mild-to-moderate AD and
mixed results were obtained. Quinn et al. (2010) were not able to
find significant effects of DHA in a quite large RCT. Nevertheless,
when administration of DHA was combined with EPA, other
clinical studies found either a subtle cognitive improvement
in a subgroup of very-mild AD (Freund-Levi et al., 2006) or
a decrease of cognitive decline rates in mild-to-moderate AD
patients (Shinto et al., 2014; Eriksdotter et al., 2015).
Among dietary interventions, fasting, calorie restriction and
ketogenic diets (KD) have also been widely proposed to reverse
obesity and T2D, being able not only to promote weight loss
but also to enhance insulin sensitivity and reduce inflammation
(Harvie et al., 2011; Myette-Cote et al., 2018). In the present
section, we will discuss the impact of these particular dietary
approaches on brain plasticity and pathological hallmarks as
potential therapies for AD-like neurodegeneration. Fasting can
be defined as a period of food deprivation. It has been associated
with different socio-cultural factors from religion to periods of
food scarcity and it was later related to increased lifespan in
several species (Brandhorst et al., 2015). There are different
fasting protocols described in the literature, mainly due to length
and frequency variations. Essentially, intermittent or periodic
fasting and dietary restriction are very similar approaches since
the main phenomenon is the time restriction of food intake. At
the level of the metabolic response and in a similar fashion as
ketogenic diets, these dietary interventions lead to an increase of
ketone bodies, producing relevant changes in glucose metabolism
(Wilhelmi de Toledo et al., 2019). Ketogenic diet is mainly
featured by a very high-fat and low-carbohydrate intake and can
be difficult to sustain, therefore the increase of ketone bodies can
also be achieved by administering medium chain triglycerides
(MCT) without changing the diet (Reger et al., 2004; Henderson
et al., 2009; Taylor et al., 2018). In Table 1, we can find a
selection of relevant clinical studies addressing their impact on
cognitive function.
As regards experimental studies, KD, intermittent fasting
(IF) or dietary restriction (DR) have shown to promote
improved glucose metabolism together with anti-inflammatory
and cognitive amelioration in animal models of AD. For instance,
KD exposed 3xTg-AD mice exhibited enhanced memory and
learning ability in addition to decreased hippocampal Aβ
deposition (Kashiwaya et al., 2013), while APP/V7/171 transgenic
female mice also showed decreased levels of Aβ along with
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positive metabolic changes in response to KD, though the
behavioral alterations were not significantly improved (Van der
Auwera et al., 2005). As for intermittent fasting, it was recently
shown that App NL-G-F mice maintained in an IF protocol
alternating ad libitum and fasting days for a month, exhibited an
adaptive response to acute fasting with improved memory and
anxiety-related outcomes. The behavioral profile amelioration
occurred concomitantly with synaptic remodeling dependent of
SIRT3 mitochondrial deacetylase (Liu et al., 2019), suggesting
that IF can modulate oxidative stress, thereby constituting a
potential approach to mitigate AD-related cognitive impairment
and synaptic dysfunction. In the same line, our group and
others have shown that DR represents a moderate and feasible
schedule capable of improving cognitive function in aged wild
type (Ma et al., 2018) and PDAPP-J20 transgenic mice (Gregosa
et al., 2019). In the latter, we found that three cycles of DR
alternated with ad libitum feeding between 6.5 and 8 months of
age not only was able to improve spatial memory but was also
associated with enhanced neurogenesis and decreased Aβ load in
the hippocampus. Moreover, periodic DR prevented microglial
activation and promoted a decrease in the levels of hippocampal
IL-1β, thus counteracting the neuroinflammatory status.
Microbiota Modulation
The inflammatory status in the mentioned structures of the
CNS present in the context of metabolic diseases has been
associated with a low-grade chronic inflammation response both
detected and potentially triggered in the periphery. One of
the possible mechanisms corresponds to alterations of the gut
microbiota affecting the microbiome-gut-brain axis. Obesity-
related disorders are often reported to co-occur with dysbiosis-
associated inflammation and interventions with probiotics
and related bioactive compounds have been able to reverse
inflammatory parameters and ameliorate cognitive decline and
hippocampal plasticity alterations, such as LTP and synaptic
activity (Solas et al., 2017). Gut microbiome diversity alterations
have been associated with the AD-like pathological context,
not only in relation to the gut but also BBB dysfunction
(Vogt et al., 2017). Therefore, probiotic supplementation has
been proposed as a potentially beneficial strategy to improve
AD symptoms by modulating microbiota and ultimately the
gut-brain axis. Probiotics are living microorganisms that have
shown to elicit beneficial effects in the host, preventing
infections, obesity-related alterations as well as promoting CNS
positive modulation (Hutchinson et al., 2020). As it can be
appreciated in the studies cited in Table 1, different probiotic
formulations have shown to ameliorate cognitive function in
patients with MCI or AD. For instance, Tamtaji et al. (2019)
showed that the administration of a probiotic therapy containing
L. acidophilus, B. bifidum, and Bifidobacterium longum co-
supplemented with selenium, present in several beneficial
probiotic formulations, was able to promote improved cognitive
performance as well as an ameliorated metabolic profile.
Peripheral inflammation decreased together with enhanced
insulin sensitivity and an ameliorated lipidemic profile (Tamtaji
et al., 2019). Consistently with this data, there is also experimental
evidence of positive outcomes in 3x-Tg mice that were
given selenium-enriched yeast for 3 months. Interestingly,
spatial memory was improved concomitantly with reduced
neuroinflammation, GSK3β-dependent Tau phosphorylation and
increased expression of synaptic proteins in the cortex and
hippocampus (Zhang et al., 2017). In the same line, in a pilot
study and a larger RCT (Kobayashi et al., 2019a,b), analyzed
the impact of a 6- or 3-month probiotic supplementation
with Bifidobacterium breve A1 in aged patients with MCI,
respectively. In both cases, administration of the probiotics
resulted in improved scores at neuropsychological tests assessing
cognitive and mood status. Likewise, Bifidobacterium breve A1
administration to mice that were i.c.v- injected with Aβ elicited
an anti-inflammatory response, along with an improvement
of cognitive decline (Kobayashi et al., 2017). Taken together,
this experimental and clinical data suggests that probiotic
supplementation may constitute a beneficial lifestyle approach
to enrich and reshape gut microbiome, thereby exerting an
anti-inflammatory and anti-neurodegenerative response to AD
pathological context.
CONCLUDING REMARKS
The alarming prevalence of both AD and obesity- related
metabolic disorders and the consequent implications in public
health strongly require the rise of efficient therapeutic solutions.
The fact that metabolic alterations are risk factors for the
development of age-related dementia not only reinforces the
relevance of the problem but also provides useful insight as
regards potential research fields to further explore. Therefore, this
review intended to highlight the shared pathways at the interface
of these pathologies as potential targets to override AD burden.
Insulin resistance and chronic inflammation are two synergic
phenomena underlying the pathogenesis of metabolic diseases
as well as the development of the wide variety of associated
disorders, including AD-like neurodegeneration. Therapeutic
approaches targeting these interacting factors could be proposed
as potential AD treatments even though data is variable and
there is an important gap between experimental evidence from
animal models and replication in clinical trials. Several factors
should be taken into account. Firstly, the specific origin or
etiology of the diseased context might differ considerably, with
a variable substrate to address mainly according to age but
also as regards pre-existing or co-occurring morbidities, namely
developmental traits, obesity, diabetes and genetic predisposition.
Secondly, and in association with the lack of etiology certainty
in AD patients, the proposed therapies may be targeting either
causes or mere symptoms, with an additional factor: the targeted
pathways redundancy and compensatory mechanisms. In that
sense, lifestyle approaches may tackle different pathological
components in a more extensive/holistic manner, serving also as
powerful preventive strategies.
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